# A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)

> **NCT06953583** · PHASE3 · RECRUITING · sponsor: **Biogen** · enrollment: 255 (estimated)

## Conditions studied

- Friedreich Ataxia

## Interventions

- **DRUG:** Omaveloxolone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06953583
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-09
- **Primary completion:** 2027-11-16
- **Final completion:** 2029-11-22
- **Target enrollment:** 255 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06953583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06953583, "A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06953583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*